Robert F. Kennedy Jr. Evaluates Covid Vaccine Risks and Pushes Drug Ad Ban

Health Secretary Robert F. Kennedy Jr. has terminated the emergency use authorization for the Pfizer‑BioNTech COVID‑19 vaccine and issued a detailed re‑assessment of its risk‑benefit balance. His analysis argues that the widely quoted 95% efficacy figure stems from a narrow endpoint and limited follow‑up, while safety data show a numerical excess of adverse events across several categories, calling into question whether the vaccine’s clinical benefits outweigh its harms.

Kennedy also pledged to ban direct‑to‑consumer pharmaceutical advertising. The FDA has proposed a rule requiring drug ads to disclose all risk information, a measure that could effectively end TV and radio ads due to length requirements. However, the Trump administration has not set a firm timeline for the rule, and pharmaceutical companies are lobbying against it. Kennedy’s dual initiatives target both vaccine policy and drug‑marketing practices in the United States.